sTREM2 (Soluble TREM2) - Biomarker

sTREM2 (Soluble TREM2) - Biomarker

Overview

sTREM2 (soluble Triggering Receptor Expressed on Myeloid Cells 2) is a breakdown product of TREM2 that serves as a critical biomarker for microglial activity and neuroinflammation in neurodegenerative diseases. Unlike membrane-bound TREM2, sTREM2 can be measured in cerebrospinal fluid (CSF) and blood, providing a window into microglial function in the living brain.

Properties

| Property | Value |
|----------|-------|
| Category | Microglial Activation Biomarker |
| Target | TREM2 Signaling / Microglial Function |
| Sample Type | CSF, Blood (plasma/serum) |
| Diseases | Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease |
| Normal Range | CSF: 2-15 ng/mL; Plasma: 0.5-5 ng/mL |

Molecular Biology

Generation of sTREM2

sTREM2 is generated through two primary mechanisms:

Proteolytic cleavage — ADAM10/ADAM17 shed the extracellular domain of TREM2

Alternative splicing — produces soluble isoforms lacking the transmembrane domain

The soluble form retains the ligand-binding immunoglobulin-like domain, allowing it to compete with membrane-bound TREM2 for ligands.

Structure

• Molecular weight: ~25-30 kDa (glycosylated)
• Domain: Single V-type immunoglobulin-like domain
• Source: Microglia, macrophages, dendritic cells

Biological Function

...

sTREM2 (Soluble TREM2) - Biomarker

Overview

sTREM2 (soluble Triggering Receptor Expressed on Myeloid Cells 2) is a breakdown product of TREM2 that serves as a critical biomarker for microglial activity and neuroinflammation in neurodegenerative diseases. Unlike membrane-bound TREM2, sTREM2 can be measured in cerebrospinal fluid (CSF) and blood, providing a window into microglial function in the living brain.

Properties

| Property | Value |
|----------|-------|
| Category | Microglial Activation Biomarker |
| Target | TREM2 Signaling / Microglial Function |
| Sample Type | CSF, Blood (plasma/serum) |
| Diseases | Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease |
| Normal Range | CSF: 2-15 ng/mL; Plasma: 0.5-5 ng/mL |

Molecular Biology

Generation of sTREM2

sTREM2 is generated through two primary mechanisms:

Proteolytic cleavage — ADAM10/ADAM17 shed the extracellular domain of TREM2

Alternative splicing — produces soluble isoforms lacking the transmembrane domain

The soluble form retains the ligand-binding immunoglobulin-like domain, allowing it to compete with membrane-bound TREM2 for ligands.

Structure

• Molecular weight: ~25-30 kDa (glycosylated)
• Domain: Single V-type immunoglobulin-like domain
• Source: Microglia, macrophages, dendritic cells

Biological Function

sTREM2 acts as a decoy receptor that:

• Modulates microglial activation thresholds
• Competes with mTREM2 for pathogenic ligands (Aβ, lipids)
• May have pro-inflammatory or anti-inflammatory effects depending on context
• Regulates microglial survival, proliferation, and phagocytosis

Role in Disease

Alzheimer's Disease

sTREM2 in AD shows a biphasic pattern:

• Early AD (MCI) — sTREM2 is elevated, suggesting compensatory microglial activation
• Moderate-Severe AD — sTREM2 may decrease as microglial function exhausts

Key findings:

• CSF sTREM2 correlates with CSF p-tau and total tau
• Associates with TREM2 risk variants (R47H, R62H)
• Predicts conversion from MCI to AD
• Reflects microglial response to amyloid pathology

Frontotemporal Dementia (FTD)

In FTD, particularly with GRN mutations:

• Elevated CSF sTREM2 compared to controls
• Reflects ongoing neuroinflammation
• May differentiate FTD subtypes

Parkinson's Disease

In PD:

• CSF sTREM2 is altered in GBA mutation carriers
• Correlates with cognitive decline in PD
• May reflect microglial activation secondary to α-syn pathology

Clinical Applications

Diagnostic Utility

sTREM2 shows promise for AD diagnosis:

| Comparison | Sensitivity | Specificity | AUC |
|------------|-------------|-------------|-----|
| AD vs. Controls | 70-80% | 65-75% | 0.75-0.82 |
| MCI-AD vs. MCI-stable | 65-75% | 60-70% | 0.70-0.78 |
| AD vs. FTD | 60-70% | 55-65% | 0.65-0.72 |

Prognostic Value

• Cognitive decline — baseline sTREM2 predicts future MMSE decline
• Brain atrophy — correlates with hippocampal atrophy rate
• Treatment response — may predict response to anti-amyloid therapies

Biomarker Combinations

Best performance when combined with:

• Aβ42/40 ratio — amyloid status
• p-tau — tau pathology
• NfL) — neurodegeneration

Detection Methods

| Method | Advantages | Limitations |
|--------|------------|-------------|
| ELISA | Specific, quantitative | Requires validation |
| Simoa | Ultra-sensitive | Limited standardization |
| Western Blot | Confirms isoform pattern | Low throughput |

Sample Handling

• CSF: Collect via lumbar puncture, store at -80°C, avoid repeated freeze-thaw
• Plasma: Collect in EDTA tubes, centrifuge within 2 hours, store at -80°C
• Standardization: Use same collection protocol across timepoints

Therapeutic Implications

sTREM2 is a therapeutic target:

TREM2 Agonists

• AL002 — anti-TREM2 antibody (activating)
• AL003 — anti-TREM2 antibody (different epitope)
• Aim to enhance microglial function

TREM2 Modulation

• sTREM2-Fc fusion proteins — engineered soluble TREM2
• Gene therapy — AAV-mediated TREM2 expression

Monitoring

• sTREM2 levels may serve as pharmacodynamic marker
• Correlates with microglial response to therapy

Cross-Linking

sTREM2 is linked to the following topics:

• TREM2 Gene
• TREM2 Signaling
• Microglia
• Neuroinflammation Pathway
• Alzheimer's Disease Biomarkers
• CSF Biomarkers
• GFAP
• YKL-40

TREM2 Genetics and Risk Variants

Alzheimer's Disease Risk Variants

The TREM2 gene (chr6p21) contains several variants that influence AD risk:

| Variant | Risk (OR) | Effect on sTREM2 |
|---------|-----------|------------------|
| R47H | 2-4x increased | Reduced ligand binding |
| R62H | 1.5-2x increased | Moderate effect |
| R62L | 1.3x increased | Mild effect |
| H157Y | 2-3x increased | Altered shedding |
| T96K | 1.5x increased | Modified function |

These variants affect:

• Ligand binding: Reduced recognition of Aβ, lipids
• Cell surface expression: Altered mTREM2/sTREM2 ratio
• Signaling: Impaired microglial activation
• sTREM2 levels: Variable effects depending on variant

TREM2 Biology in Neurodegeneration

• Rare variants: Cause early-onset dementia (POCD)
• Common variants: Modify late-onset AD risk
• Expression: Upregulated in AD, PD, ALS brain tissue

Research Challenges and Future Directions

Current Limitations

Biphasic pattern: Difficult to interpret in isolation

Assay standardization: Variability between methods

Disease specificity: Elevated in multiple conditions

Stage dependency: Different patterns across disease stages

Emerging Research Areas

• sTREM2 isoforms: Characterization of different splice forms
• Functional studies: sTREM2 as therapeutic agent
• Combination biomarkers: sTREM2 + p-tau + Aβ panels
• Genetic stratification: Using TREM2 genotype in clinical trials
• Therapeutic monitoring: sTREM2 as pharmacodynamic marker

Clinical Trial Applications

sTREM2 is being used to monitor TREM2-targeted therapies:

| Trial | Drug | sTREM2 Readout |
|-------|------|----------------|
| NCT05171430 | AL002 | Increased sTREM2 expected |
| NCT05182827 | AL003 | Dose-dependent changes |
| Various | TREM2 AAV | Biomarker modulation |

Biomarker Combinations

sTREM2 in combination with other biomarkers:

| Combination | AUC | Clinical Application |
|-------------|-----|---------------------|
| sTREM2 + p-tau181 | 0.82-0.88 | AD diagnosis |
| sTREM2 + Aβ42/40 | 0.78-0.85 | Amyloid status |
| sTREM2 + NfL | 0.75-0.82 | Disease progression |
| sTREM2 + GFAP | 0.80-0.86 | Neuroinflammation panel |

The combination of sTREM2 with established AD biomarkers (p-tau, Aβ) improves diagnostic accuracy and provides insight into microglial response to pathology.

Background

The study of Strem2 (Soluble Trem2) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

^{<a href=#references>[1]</a>} SUÁREZ-CALVET M, et al. sTREM2 cerebrospinal fluid levels are a dynamic biomarker for activation of the innate immune system in healthy aging. Nat Neurosci. 2019;22(3):428-437.

^{<a href=#references>[2]</a>} Yeh FL, et al. TREM2 in the pathogenesis of AD: a potential therapeutic target? Neuron. 2016;92(5):931-939.

^{<a href=#references>[3]</a>} Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair microglial function. Nat Neurosci. 2014;17(11):1339-1347.

^{<a href=#references>[4]</a>} Ewers M, et al. CSF sTREM2 and cognitive performance in non-demented elderly. Neurobiol Aging. 2020;95:114-122.

^{<a href=#references>[5]</a>} Piccio L, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with CSF biomarkers. Neurology. 2017;89(10):1013-1021.

^{<a href=#references>[6]</a>} Schlepckow K, et al. Enhancing protective microglial activity with TREM2-targeting antibodies. Nat Neurosci. 2020;23(5):581-593.

^{<a href=#references>[7]</a>} Liu D, et al. sTREM2 in cerebrospinal fluid as a biomarker in neurodegenerative diseases. Alzheimers Dement. 2021;17(12):1923-1934.

^{<a href=#references>[8]</a>} Sheng J, et al. TREM2 and neuroinflammation. J Neuroinflammation. 2023;20(1):45.

• TREM2 Gene
• [TREM2 Agonists](treatments/trem2-agonists)
• Alzheimer's Disease Biomarkers
• CSF Biomarkers Overview
• GFAP Biomarker
• YKL-40 Biomarker
• Microglia Entity

External Links

• [TREM2 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/54206)
• [TREM2 Structure - UniProt](https://www.uniprot.org/uniprot/Q9NZC4)
• [AL002 Clinical Trial](https://clinicaltrials.gov/ct2/show/NCT05171430)

Pathway Diagram

See Also

• [ABCA7 (ATP-Binding Cassette Transporter A7)](/wiki/genes-abca7) — associated_with

Pathway Diagram

The following diagram shows the key molecular relationships involving sTREM2 (Soluble TREM2) - Biomarker discovered through SciDEX knowledge graph analysis: